Prosecution Insights
Last updated: April 19, 2026
Application No. 19/362,169

SYSTEMS AND METHODS TO DETECT RARE MUTATIONS AND COPY NUMBER VARIATION

Non-Final OA §DP
Filed
Oct 17, 2025
Examiner
HORLICK, KENNETH R
Art Unit
1681
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Guardant Health Inc.
OA Round
1 (Non-Final)
79%
Grant Probability
Favorable
1-2
OA Rounds
2y 6m
To Grant
94%
With Interview

Examiner Intelligence

Grants 79% — above average
79%
Career Allow Rate
817 granted / 1035 resolved
+18.9% vs TC avg
Strong +15% interview lift
Without
With
+15.1%
Interview Lift
resolved cases with interview
Typical timeline
2y 6m
Avg Prosecution
24 currently pending
Career history
1059
Total Applications
across all art units

Statute-Specific Performance

§101
5.3%
-34.7% vs TC avg
§103
38.4%
-1.6% vs TC avg
§102
6.5%
-33.5% vs TC avg
§112
15.2%
-24.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1035 resolved cases

Office Action

§DP
Notice of Pre-AIA or AIA Status 1. The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . OBJECTION 2. The specification is objected to because of the following informality: the continuation information must be updated to indicate the issue of the parent ‘072 application as US 12,319,972. NON-PRIOR ART REJECTIONS 3. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. 4. Claims 1-22 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-13 of U.S. Patent No. 11,773,453. Although the claims at issue are not identical, they are not patentably distinct from each other because the patented claims and the pending claims are related as species-genus. That is, the pending claims are broader in that all of the limitations within steps (a) – (d) are included within the more limited patented claims in steps (a) – (h); thus, the patented claims are a species within the genus of the pending claims. 5. Claims 1-22 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-18 of U.S. Patent No. 11,879,158. Although the claims at issue are not identical, they are not patentably distinct from each other because the patented claims and the pending claims are related as species-genus. That is, the pending claims are broader in that all of the limitations within steps (a) – (d) are included within the more limited patented claims in steps (a) – (e); thus, the patented claims are a species within the genus of the pending claims. ALLOWABLE SUBJECT MATTER 6. Claims 1-22 are free of the prior art, but they are rejected for another reason. For the sake of completeness, the Office notes that although there is some overlap in language between the pending claim set and the patented claim set in US 12,252,749, no issue of nonstatutory double patenting has been found. The closest prior art, made of record during previous prosecution, is Narayan et al. (2012), which teaches steps (a) – (c) and part of step (d) of independent claim 1 with respect to measuring cancer mutations, but does not teach analysis of polymorphic forms including methylation, hypermethylation, and/or hydroxymethylation, and using one or more bioinformatics processes to detect methylation profiles. Clancy et al. (US 2011/0237444) and Bielas (US 10,011,871) disclose the importance of detecting and measuring methylation events and patterns in nucleic acids, including cell-free nucleic acids in blood, but no suggestion has been found in the prior art to modify the specific tagging/sequencing methodology of Narayan et al. by applying it to methylation analysis and methylation profiles. CONCLUSION 7. No claims are allowable. 8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to KENNETH R HORLICK whose telephone number is (571)272-0784. The examiner can normally be reached Mon. - Thurs. 8:30 - 6:30. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Gary Benzion can be reached at 571-272-0782. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. 02/11/26 /KENNETH R HORLICK/ Primary Examiner, Art Unit 1681
Read full office action

Prosecution Timeline

Oct 17, 2025
Application Filed
Feb 11, 2026
Non-Final Rejection — §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12584159
SEPARATION OF NUCLEIC ACID COMPONENT COMPOUNDS ON ZWITTERIONIC STATIONARY PHASES
2y 5m to grant Granted Mar 24, 2026
Patent 12577613
SYSTEMS AND METHODS FOR SELECTIVE DNA MULTIPLE DISPLACEMENT AMPLIFICATION OF A DNA MIXTURE;
2y 5m to grant Granted Mar 17, 2026
Patent 12576399
DEVICES AND METHODS FOR ANALYZING BIOLOGICAL SAMPLES
2y 5m to grant Granted Mar 17, 2026
Patent 12571048
FRET-BASED ANALYTES DETECTION AND RELATED METHODS AND SYSTEMS
2y 5m to grant Granted Mar 10, 2026
Patent 12565674
METHODS AND SYSTEMS FOR ANALYZING NUCLEIC ACID MOLECULES
2y 5m to grant Granted Mar 03, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
79%
Grant Probability
94%
With Interview (+15.1%)
2y 6m
Median Time to Grant
Low
PTA Risk
Based on 1035 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month